Hunan Hengguang Technology Co (301118) Fair Value & Analysis
Basic Materials · CN · Market cap 3.2B CNY
Analysis
Hunan Hengguang Technology Co (301118) currently trades at ¥30.80, while our model-based Fair Value estimate is ¥14.73 — implying the stock looks roughly 52.2% overvalued today. We read business quality at 92/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Hunan Hengguang Technology Co., Ltd. engages in the research, development, manufacture, sale, and service of new chemical materials. It provides chlorinated products, such as sodium chlorate, alkali, liquid chlorine, and hydrochloric acid; and vulcanizing products, including fuming and reagent sulphuric acid, sulfamic acid, sodium pyrosulfite, sodium sulfite, and magnesium sulphate heptahydrate. The company also offers chemicals and materials comprising calcium aluminum hydrotalcite, cysteamine hydrochloride, amino sulfonic acid, germanium oxide, and zone melting germanium ingot, as well as refined acid and magnesium sulfate fertilizer. In addition, it provides sulfur solid waste treatment services, as well as engages in development of environmental protection technology. Further, it provides products to various parts of Jiangxi Province, Inner Mongolia, Sichuan, Guizhou, etc., as well as exports to the European Union, Southeast Asia, Japan, South Korea, Russia, and other countries.…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.